4D pharma plc Shareholder Equity

2021-12-31: Common Stock, Value, IssuedUSD $646.00K; Additional Paid in CapitalUSD $236.26M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-24.32M; Retained Earnings (Accumulated Deficit)USD $-180.17M.
2021-06-30: Common Stock, Value, IssuedUSD $646.00K; Additional Paid in CapitalUSD $235.64M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-23.47M; Retained Earnings (Accumulated Deficit)USD $-173.16M.
2020-12-31: Common Stock, Value, IssuedUSD $479.00K; Additional Paid in CapitalUSD $210.88M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-24.15M; Retained Earnings (Accumulated Deficit)USD $-148.24M.
2020-06-30: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD (m).

4D pharma plc Shareholder Equity

Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.

Period end	Common Stock, Value, Issued USD	Additional Paid in Capital USD	Accumulated Other Comprehensive Income (Loss), Net of Tax USD	Retained Earnings (Accumulated Deficit) USD	Stockholders' Equity Attributable to Parent USD	APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD	Adjustments to Additional Paid in Capital, Warrant Issued USD
2021-12-31	$646.00K	$236.26M	$-24.32M	$-180.17M	$32.42M	12 month · $711.00K	(m)
2021-06-30	$646.00K	$235.64M	$-23.47M	$-173.16M	$39.65M	6 month · $85.00K	(m)
2020-12-31	$479.00K	$210.88M	$-24.15M	$-148.24M	$38.97M	12 month · $331.00K	12 month · $3.35M
2020-06-30	(m)	(m)	(m)	(m)	$40.88M	6 month · $139.00K	6 month · $3.27M
2019-12-31	$266.00K	$174.38M	$-25.71M	$-117.74M	$31.19M	12 month · $340.00K	(m)
2018-12-31	(m)	(m)	(m)	(m)	$60.07M	12 month · $363.00K	(m)
2017-12-31	(m)	(m)	(m)	(m)	$96.30M	(m)	(m)